|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM308683528 |
| 003 |
DE-627 |
| 005 |
20250227031705.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108420
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1028.xml
|
| 035 |
|
|
|a (DE-627)NLM308683528
|
| 035 |
|
|
|a (NLM)32283324
|
| 035 |
|
|
|a (PII)S1521-6616(20)30259-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hedrich, Christian M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a COVID-19 - Considerations for the paediatric rheumatologist
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.05.2020
|
| 500 |
|
|
|a Date Revised 28.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020. Published by Elsevier Inc.
|
| 520 |
|
|
|a The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lifes across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting "cytokine storm" that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a ARDS
|
| 650 |
|
4 |
|a COVID
|
| 650 |
|
4 |
|a Cytokine storm
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a Paediatric
|
| 650 |
|
4 |
|a Rheumatology
|
| 650 |
|
4 |
|a SARS
|
| 650 |
|
4 |
|a SARS-CoV2
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 214(2020) vom: 01. Mai, Seite 108420
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:214
|g year:2020
|g day:01
|g month:05
|g pages:108420
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108420
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 214
|j 2020
|b 01
|c 05
|h 108420
|